Nox3 siRNA (h)

Protocol tips

Upstream tips	Protocol tips	Downstream tips
	siRNA concentration-50nM Add diluted siRNA to diluted Lipofectamine Reagent Incubate for 5 min at RT and add to cells. Incubate cells for 2 days at 37°C.

Protocol tips
siRNA concentration-50nM Add diluted siRNA to diluted Lipofectamine Reagent Incubate for 5 min at RT and add to cells. Incubate cells for 2 days at 37°C.

Publication protocol

DNA and siRNA transfections were performed using Lipofectamine 2000 according to the manufacturer's recommendations. For general silencing experiments, nonsilencing siRNA (50nM) or gene-specific siRNA (50nM) was transfected into Beas-2B. The nonsilencing siRNA was used as a negative control. After 48 h transfection, the cells were starved for 16 h followed by treatment with or without Cr(VI). For generation of stable cell lines, after transfection of SOD1, SOD2, CAT, shRNA-p47phox, or their responding vectors using Lipofectamine 2000, cells were cultured in complete medium in the presence of 1000 μg/ml G418. After 3 weeks, cell clones resistant to G418 were isolated. Transfected cells were routinely cultured in the presence of 800 μg/ml of G418. Overexpression of SOD1, SOD2, CAT, and suppressed p47phox protein production were confirmed by immunoblotting as described previously (Wang et al., 2010).

Full paper   Login or join for free to view the full paper.

Reviews

Discussion

Papers

Check out relevant papers found by Labettor's AI that are relevant for performing siRNA / miRNA gene silencing Human - BEAS-2B NOX3 using Nox3 siRNA (h) from Santa Cruz Biotechnology.

Manufacturer protocol

Download the product protocol from Santa Cruz Biotechnology for Nox3 siRNA (h) below.

Download manufacturer protocol

Videos

Check out videos that might be relevant for performing siRNA / miRNA gene silencing Human - BEAS-2B NOX3 using Nox3 siRNA (h) from Santa Cruz Biotechnology. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.